Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System

    March 2020 in “ Scientific Reports ”
    Jing Huang, Long Meng, Bing Yang … Hong Chen
    Studysummary This study mapped the safety profile of EGFR-TKIs by analyzing FDA adverse event reports, highlighting unexpected reactions like intestinal obstruction and hypokalaemia with gefitinib and erlotinib.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on nature.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Successful Treatment of Epidermal Growth Factor Receptor Inhibitor-Induced Alopecia with Doxycycline JAAD Case Reports · 2015
    2. Classification and Management of Skin, Hair, Nail, and Mucosal Side Effects of Epidermal Growth Factor Receptor Inhibitors European journal of cancer · 2007

    Related research 1

    1. Multidimensional Assessment of Adverse Events of Finasteride: A Real-World Pharmacovigilance Analysis Based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024 medRxiv (Cold Spring Harbor Laboratory) · 2024